A national education program for pharmacists funded by the Australian Government under the Quality Use of Diagnostics, Therapeutics and Pathology program.[/caption]
While the evidence bases for both CMs and Schedule 3 sleep aids are unlikely to immediately change, a core practice consideration is the risk-benefit profile of the respective non-prescription sleep aids for the individual patient. 
Is it really insomnia?
Knowledge to practice 
If catastrophe calls, include these ‘musts’ in your plan
It’s imperative that every pharmacy have a disaster plan, a clear written procedure on what to do, to eliminate delays getting deliveries to affected areas.
HPV vaccine – protective and no riskier than placebo
HPV vaccine protects against cervical precancer in female adolescents and does not increase the risk of serious adverse effects.
This is the finding of Cochrane...
Royal Pharmaceutical Society director on the future of pharmacy
Ravi Sharma’s credentials in pharmacy are formidable. Recently appointed the Royal Pharmaceutical Society’s (RPS’s) director for England, he was also National Clinical Lead for...
Bringing pharmacists into the digital future
PSA has unveiled a new digital health report, Connecting the dots: Digitally empowered pharmacists, at the PSA19 conference.
The report, funded by the Australian Digital...
‘Devastating’ volume of clinical waste generates concern
As environmental threats become increasingly pressing, healthcare professionals are calling for changes in the way clinical waste is managed in medical settings.
In a recent...
The new normal
A new PSA report describes the digital future of Australian health care, a ‘new normal’ with pharmacists front and centre, equipped with more information...
